Fairmount Funds Management LLC holds a concentrated book of 12 stocks worth $1.5B as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened Sensei Biotherapeutics Inc. Their largest long position is Oruka Therapeutics Inc at 23% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Fairmount Funds Management LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Remedium Capital Partners, LLC | 6 / 12 | $451.6M |
| Venrock Adviser, LLC | 10 / 12 | $1.6B |
| Avidity Partners Management LP | 4 / 12 | $249.2M |
| Octagon Capital Advisors LP | 2 / 12 | $253.8M |
| Commodore Capital LP | 6 / 12 | $480.7M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3 / 12 | $2.2B |
| Spruce Street Capital LP | 4 / 12 | $117.3M |
| Paradigm Biocapital Advisors LP | 5 / 12 | $933.1M |
Ranked by the share of each fund's own book sitting in the names it shares with Fairmount Funds Management LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Oruka Therapeutics Inc COM | $352.6M | 3.71M | 23.3% | —Held | |
| 2 | Dianthus Therapeutics Inc COM | $247.3M | 2.54M | 16.3% | —Held | |
| 3 | Damora Therapeutics Inc COM NEW | $226.6M | 8.71M | 15.0% | —Held | |
| 4 | Cogent Biosciences Inc COM | $213.0M | 5.50M | 14.1% | —Held | |
| 5 | Jade Biosciences Inc COM NEW | $101.2M | 4.55M | 6.7% | —Held | |
| 6 | Enliven Therapeutics Inc COM | $94.2M | 1.86M | 6.2% | —Held | |
| 7 | Viridian Therapeutics Inc COM | $93.5M | 5.09M | 6.2% | ▲+30% Added · +1.2M sh | |
| 8 | Zenas Biopharma Inc COM | $59.9M | 2.36M | 4.0% | —Held | |
| 9 | Crescent Biopharma Inc. COM | $49.5M | 2.75M | 3.3% | —Held | |
| 10 | Apogee Therapeutics Inc COM | $39.6M | 298.6K | 2.6% | —Held | |
| 11 | Faeth Therapeutics Inc COM NEW | $18.1M | 722.0K | 1.2% | ▲New New position | |
| 12 | Inhibikase Therapeutics Inc COM NEW | $17.5M | 8.63M | 1.2% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1802528/holdings"
Use Arkolith to show Fairmount Funds Management LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.